The fibrate gemfibrozil is a NO- and haem-independent activator of soluble guanylyl cyclase: In vitro studies

British Journal of Pharmacology

Volumn 172, Issue 9, 2015, Pages 2316-2329

  Sharina, I G ^a   Sobolevsky, M ^a   Papakyriakou, A ^b   Rukoyatkina, N ^c,d   Spyroulias, G A ^e   Gambaryan, S ^c,d   Martin, E ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d SECHENOV INSTITUTE OF EVOLUTIONARY PHYSIOLOGY AND BIOCHEMISTRY   (Russian Federation)

^e UNIVERSITY OF PATRAS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; ATACIGUAT; BEZAFIBRATE; CARBOXYL GROUP; CINACIGUAT; CIPROFIBRATE; CLOFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GUANYLATE CYCLASE; ISOBUTYLMETHYLXANTHINE; LIPID; LIPOPROTEIN; NITRIC OXIDE; PROTOPORPHYRIN; VASOACTIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; CELL RECEPTOR; ENZYME ACTIVATOR; HEME; RECOMBINANT PROTEIN; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; MALE; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION; UNSPECIFIED SIDE EFFECT; VASCULAR RING; WESTERN BLOTTING; ANIMAL; BINDING SITE; DOSE RESPONSE; DRUG EFFECTS; ENZYME ACTIVATION; ENZYMOLOGY; METABOLISM; OXIDATION REDUCTION REACTION; PROTEIN TERTIARY STRUCTURE; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; THORACIC AORTA; TIME FACTOR; VASODILATATION;

ANIMALS; AORTA, THORACIC; BINDING SITES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME ACTIVATORS; GEMFIBROZIL; GUANYLATE CYCLASE; HEME; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MOLECULAR DOCKING SIMULATION; NITRIC OXIDE; OXIDATION-REDUCTION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROTEIN STRUCTURE, TERTIARY; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; SOLUBLE GUANYLYL CYCLASE; TIME FACTORS; VASODILATION; VASODILATOR AGENTS;

EID: 84926625998     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13055     Document Type: Article

References (50)

1. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, et al. (2010). Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362: 1563-1574.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: Nuclear hormone receptors. Br J Pharmacol 170: 1652-1675.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
4. Case DA, Cheatham TE 3rd, Darden T, Gohlke H, Luo R, Merz KM Jr, et al. (2005). The Amber biomolecular simulation programs. J Comput Chem 26: 1668-1688.
5. Chinetti-Gbaguidi G, Fruchart JC, Staels B, (2005). Pleiotropic effects of fibrates. Curr Atheroscler Rep 7: 396-401.
6. Chrominski M, Banach L, Karczewski M, O Proinsias K, Sharina I, Gryko D, et al. (2013). Synthesis and evaluation of bifunctional sGC regulators: optimization of a connecting linker. J Med Chem 56: 7260-7277.
7. Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, et al. (2011). Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 478: 103-109.
8. Erdmann E, Semigran MJ, Nieminen MS, Gheorghiade M, Agrawal R, Mitrovic V, et al. (2013a). Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure. Eur Heart J 34: 57-67.
9. Erdmann J, Stark K, Esslinger UB, Rumpf PM, Koesling D, de Wit C, et al. (2013b). Dysfunctional nitric oxide signalling increases risk of myocardial infarction. Nature 504 (7480): 432-436.
10. Fiser A, Sali A, (2003). Modeller: generation and refinement of homology-based protein structure models. Methods Enzymol 374: 461-491.
11. Foerster J, Harteneck C, Malkewitz J, Schultz G, Koesling D, (1996). A functional heme-binding site of soluble guanylyl cyclase requires intact N-termini of alpha 1 and beta 1 subunits. Eur J Biochem 240: 380-386.
12. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. (1987). Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317: 1237-1245.
13. Fruchart JC, Duriez P, (2006). Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (Barc) 42: 39-64.
14. Gambaryan S, Kobsar A, Rukoyatkina N, Herterich S, Geiger J, Smolenski A, et al. (2010). Thrombin and collagen induce a feedback inhibitory signaling pathway in platelets involving dissociation of the catalytic subunit of protein kinase A from an NFkappaB-IkappaB complex. J Biol Chem 285: 18352-18363.
15. Herve D, Philippi A, Belbouab R, Zerah M, Chabrier S, Collardeau-Frachon S, et al. (2014). Loss of alpha1beta1 soluble guanylate cyclase, the major nitric oxide receptor, leads to moyamoya and achalasia. Am J Hum Genet 94: 385-394.
16. Hoffmann LS, Schmidt PM, Keim Y, Schaefer S, Schmidt HH, Stasch JP, (2009). Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation. Br J Pharmacol 157: 781-795.
17. Huey R, Morris GM, Olson AJ, Goodsell DS, (2007). A semiempirical free energy force field with charge-based desolvation. J Comput Chem 28: 1145-1152.
18. Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, et al. (2010). Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 375: 1875-1884.
19. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. (2005). Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366: 1849-1861.
20. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: Reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
21. Kloss S, Bouloumie A, Mulsch A, (2000). Aging and chronic hypertension decrease expression of rat aortic soluble guanylyl cyclase. Hypertension 35 (1 Pt 1): 43-47.
22. Libby P, Ridker PM, Maseri A, (2002). Inflammation and atherosclerosis. Circulation 105: 1135-1143.
23. Lu X, Wang L, Chen S, He L, Yang X, Shi Y, et al. (2012). Genome-wide association study in Han Chinese identifies four new susceptibility loci for coronary artery disease. Nat Genet 44: 890-894.
24. Ma X, Sayed N, Beuve A, van den Akker F, (2007). NO and CO differentially activate soluble guanylyl cyclase via a heme pivot-bend mechanism. EMBO J 26: 578-588.
25. Martin E, Lee YC, Murad F, (2001). YC-1 activation of human soluble guanylyl cyclase has both heme-dependent and heme-independent components. Proc Natl Acad Sci U S A 98: 12938-12942.
26. Martin E, Sharina I, Kots A, Murad F, (2003). A constitutively activated mutant of human soluble guanylyl cyclase (sGC): implication for the mechanism of sGC activation. Proc Natl Acad Sci U S A 100: 9208-9213.
27. Martin E, Golunski E, Laing ST, Estrera A, Sharina IG, (2014). Alternative splicing impairs sGC function in aortic aneurysm. Am J Physiol Heart Circ Physiol 307 (11): H1565-H1575.
28. Martin F, Baskaran P, Ma X, Dunten PW, Schaefer M, Stasch JP, et al. (2010). Structure of cinaciguat (BAY 58-2667) bound to Nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase. J Biol Chem 285: 22651-22657.
29. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
30. Meade T, Zuhrie R, Cook C, Cooper J, (2002). Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ 325: 1139.
31. Meurer S, Pioch S, Pabst T, Opitz N, Schmidt PM, Beckhaus T, et al. (2009). Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation. Circ Res 105: 33-41.
32. Miller DB, Spence JD, (1998). Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet 34: 155-162.
33. Mindukshev I, Gambaryan S, Kehrer L, Schuetz C, Kobsar A, Rukoyatkina N, et al. (2011). Low angle light scattering analysis: a novel quantitative method for functional characterization of human and murine platelet receptors. Clin Chem Lab Med 50: 1253-1262.
34. Murad F, (2006). Shattuck Lecture. Nitric oxide and cyclic GMP in cell signaling and drug development. N Engl J Med 355: 2003-2011.
35. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl. Acids Res. 42 (Database Issue): D1098-D1106.
36. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. (1999). Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341: 410-418.
37. Ruetten H, Zabel U, Linz W, Schmidt HH, (1999). Downregulation of soluble guanylyl cyclase in young and aging spontaneously hypertensive rats. Circ Res 85: 534-541.
38. Schmidt HH, Schmidt PM, Stasch JP, (2009). NO- and haem-independent soluble guanylate cyclase activators. Handb Exp Pharmacol 191: 309-339.
39. Schmidt PM, Schramm M, Schroder H, Wunder F, Stasch JP, (2004). Identification of residues crucially involved in the binding of the heme moiety of soluble guanylate cyclase. J Biol Chem 279: 3025-3032.
40. Schultz G, (1974). General principles of assays for adenylate cyclase and guanylate cyclase activity. Methods Enzymol 38: 115-125.
41. Sharina I, Sobolevsky M, Doursout MF, Gryko D, Martin E, (2011a). Cobinamides are novel co-activators of NO receptor which target sGC catalytic domain. J Pharmacol Exp Ther 340: 723-732.
42. Sharina IG, Jelen F, Bogatenkova EP, Thomas A, Martin E, Murad F, (2008). Alpha1 soluble guanylyl cyclase (sGC) splice forms as potential regulators of human sGC activity. J Biol Chem 283: 15104-15113.
43. Sharina IG, Cote GJ, Martin E, Doursout MF, Murad F, (2011b). RNA splicing in regulation of nitric oxide receptor soluble guanylyl cyclase. Nitric Oxide 25: 265-274.
44. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC, (1998). Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98: 2088-2093.
45. Stasch JP, Evgenov OV, (2013). Soluble guanylate cyclase stimulators in pulmonary hypertension. Handb Exp Pharmacol 218: 279-313.
46. Stasch JP, Hobbs AJ, (2009). NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb Exp Pharmacol 191: 277-308.
47. Vita JA, (2011). Endothelial function. Circulation 124: e906-e912.
48. Wells PS, Holbrook AM, Crowther NR, Hirsh J, (1994). Interactions of warfarin with drugs and food. Ann Intern Med 121: 676-683.
49. Xu J, Zou MH, (2009). Molecular insights and therapeutic targets for diabetic endothelial dysfunction. Circulation 120: 1266-1286.
50. Zamani P, Greenberg BH, (2013). Novel vasodilators in heart failure. Curr Heart Fail Rep 10: 1-11.